ANI Pharmaceuticals, Inc. (ANIP) – What Are Analysts Saying About This Stock?

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $100.00.

ANIP has been the topic of a number of recent research reports. Guggenheim upped their price target on ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Oppenheimer started coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price target for the company. Finally, Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the sale, the vice president owned 73,424 shares of the company’s stock, valued at $5,403,272.16. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the transaction, the director directly owned 26,762 shares in the company, valued at approximately $1,914,285.86. This represents a 3.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 27,250 shares of company stock worth $1,977,496. 8.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals in the first quarter worth $28,000. Versant Capital Management Inc grew its stake in shares of ANI Pharmaceuticals by 103.3% during the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $32,000. USA Financial Formulas purchased a new position in ANI Pharmaceuticals during the third quarter valued at $39,000. Finally, Sterling Capital Management LLC grew its holdings in ANI Pharmaceuticals by 850.0% during the third quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock valued at $50,000 after purchasing an additional 612 shares during the period. Institutional investors own 76.05% of the company’s stock.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
• Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
• Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
• Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $67.41 on Monday. The company has a quick ratio of 2.33, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The stock has a market cap of $1.55 billion, a PE ratio of 13.43, a PEG ratio of 2.17 and a beta of 0.45. ANI Pharmaceuticals has a 12-month low of $67.14 and a 12-month high of $95.45. The business has a 50-day simple moving average of $72.52 and a two-hundred day simple moving average of $77.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.18 by $0.52. The firm had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. ANI Pharmaceuticals had a return on equity of 28.34% and a net margin of 11.22%. The company’s quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.04 earnings per share. Analysts anticipate that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.